How to buy Olema Pharmaceuticals stock (Olema Pharmaceuticals)

Olema Pharmaceuticals is a biotechnology business based in the US. Olema Pharmaceuticals shares (OLMA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.32 – an increase of 8.03% over the previous week. Olema Pharmaceuticals employs 74 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Olema Pharmaceuticals stock

Buy Olema Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Olema Pharmaceuticals stock price (NASDAQ: OLMA)

Use our graph to track the performance of OLMA stocks over time.

Olema Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$6.32
52-week range	$5.56 - $16.78
50-day moving average more info button	$10.52
200-day moving average more info button	$11.52
Wall St. target price	$28.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.28

Is it a good time to buy Olema Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Olema Pharmaceuticals price performance over time

Historical closes compared with the close of $6.3 from 2024-12-23

1 week (2024-12-18)	7.69%
1 month (2024-11-25)	-29.29%
3 months (2024-09-25)	-49.19%
6 months (2024-06-25)	-46.29%

1 year (2023-12-22)	-54.28%
2 years (2022-12-23)	137.74%
3 years (2021-12-23)	9.91
5 years (2019-12-21)	N/A

Olema Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-32.48%
Return on equity TTM	-51.76%
Profit margin	0%
Book value	$3.47
Market Capitalization more info button	$431.8 million

TTM: trailing 12 months

Olema Pharmaceuticals share dividends

We're not expecting Olema Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Olema Pharmaceuticals share price volatility

Over the last 12 months, Olema Pharmaceuticals's shares have ranged in value from as little as $5.5562 up to $16.775. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Olema Pharmaceuticals's is 2.034. This would suggest that Olema Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Olema Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Puma Biotechnology (PBYI.US): 1.08
• Xenetic Biosciences (XBIO.US): 2.263
• Inovio Pharmaceuticals (INO.US): 0.833
• Oncorus Inc (ONCR.US): 1.954

Olema Pharmaceuticals overview

Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Olema Pharmaceuticals is owned by insiders or institutions?
Currently 3.802% of Olema Pharmaceuticals shares are held by insiders and 105.774% by institutions. How many people work for Olema Pharmaceuticals?
Latest data suggests 74 work at Olema Pharmaceuticals. When does the fiscal year end for Olema Pharmaceuticals?
Olema Pharmaceuticals's fiscal year ends in December. Where is Olema Pharmaceuticals based?
Olema Pharmaceuticals's address is: 780 Brannan Street, San Francisco, CA, United States, 94103 What is Olema Pharmaceuticals's ISIN number?
Olema Pharmaceuticals's international securities identification number is: US68062P1066